These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10220869)

  • 1. Troglitazone, an euglycemic antidiabetic drug.
    Vyas K; Sivalakshmidevi A; Prabhakar C; Reddy GO
    Acta Crystallogr C; 1999 Mar; 55 ( Pt 3)():411-3. PubMed ID: 10220869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of an antidiabetic agent, (+/-)-5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2,4-dioxothiazollidine, troglitazone dihydrate.
    Kobayashi K; Fukuhara H; Hata T
    Anal Sci; 2001 Mar; 17(3):467-8. PubMed ID: 11990631
    [No Abstract]   [Full Text] [Related]  

  • 3. Photooxidation of troglitazone, a new antidiabetic drug.
    Fu Y; Sheu C; Fujita T; Foote CS
    Photochem Photobiol; 1996 May; 63(5):615-20. PubMed ID: 8628753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
    Reddy KA; Lohray BB; Bhushan V; Reddy AS; Rao Mamidi NV; Reddy PP; Saibaba V; Reddy NJ; Suryaprakash A; Misra P; Vikramadithyan RK; Rajagopalan R
    J Med Chem; 1999 Aug; 42(17):3265-78. PubMed ID: 10464013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045.
    Yoshioka T; Aizawa Y; Fujita T; Nakamura K; Sasahara K; Kuwano H; Kinoshita T; Horikoshi H
    Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):2124-5. PubMed ID: 1797433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical and crystal structure analyses of the antidiabetic agent troglitazone.
    Kobayashi K; Fukuhara H; Hata T; Sekine A; Uekusa H; Ohashi Y
    Chem Pharm Bull (Tokyo); 2003 Jul; 51(7):807-14. PubMed ID: 12843587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural studies on the impurities of troglitazone.
    Moses Babu J; Nageshwar D; Ravindra Kumar Y; Prabhakar C; Sarma MR; Om Reddy G; Vyas K
    J Pharm Biomed Anal; 2003 Feb; 31(2):271-81. PubMed ID: 12609666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic stereoselectivity of troglitazone, an antidiabetic agent, in the KK mouse.
    Izumi T; Enomoto S; Hoshiyama K; Sasahara K; Sugiyama Y
    Biopharm Drug Dispos; 1997 May; 18(4):305-24. PubMed ID: 9158879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical property of troglitazone, an equal mixture of four stereoisomers.
    Suzuki N; Kasahara K; Hasegawa H; Kawasaki T
    Int J Pharm; 2002 Nov; 248(1-2):71-80. PubMed ID: 12429461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry.
    Baillie TA; Kassahun K
    Adv Exp Med Biol; 2001; 500():45-51. PubMed ID: 11764978
    [No Abstract]   [Full Text] [Related]  

  • 12. A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance.
    Cossy J; Menciu C; Rakotoarisoa H; Kahn PH; Desmurs JR
    Bioorg Med Chem Lett; 1999 Dec; 9(24):3439-40. PubMed ID: 10617087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
    Nomura M; Kinoshita S; Satoh H; Maeda T; Murakami K; Tsunoda M; Miyachi H; Awano K
    Bioorg Med Chem Lett; 1999 Feb; 9(4):533-8. PubMed ID: 10098657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troglitazone has a scavenging effect on reactive oxygen species.
    Inoue I; Katayama S; Takahashi K; Negishi K; Miyazaki T; Sonoda M; Komoda T
    Biochem Biophys Res Commun; 1997 Jun; 235(1):113-6. PubMed ID: 9196046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct chiral separation of troglitazone stereoisomers using reversed-phase high-performance liquid chromatography.
    Suzuki N; Takemura A; Miyamoto A; Yoshioka T; Tsutsumi S; Kawasaki T
    J Pharm Biomed Anal; 2002 Oct; 30(3):823-36. PubMed ID: 12367708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on compounds with antioxidant activity--development of hypoglycemic agents, troglitazone (CS-045)].
    Yoshioka T; Fujita T
    Yakugaku Zasshi; 1997 Sep; 117(9):597-610. PubMed ID: 9357328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
    Huang JW; Shiau CW; Yang YT; Kulp SK; Chen KF; Brueggemeier RW; Shapiro CL; Chen CS
    Mol Pharmacol; 2005 Apr; 67(4):1342-8. PubMed ID: 15653552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thiazolidinediones--a new class of oral antidiabetic drugs].
    Jermendy G; Csermely P
    Orv Hetil; 2001 Jul; 142(29):1547-54. PubMed ID: 11494746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity.
    Dea MK; Van Citters GW; Ader M; Mittelman SD; Sunehag AL; Bergman RN
    Diabetes; 2000 Dec; 49(12):2087-93. PubMed ID: 11118011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)-thiazolidine-2 ,4-dio ne.
    Ueda N; Nomura Y; Muta Y; Matsuzaki Y; Hayashibe M; Ino Y; Suzuki S; Kurumi M
    Arzneimittelforschung; 1998 Jun; 48(6):651-7. PubMed ID: 9689422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.